Immune drug shows promise for rare HPV throat tumors
NCT ID NCT02632344
First seen May 14, 2026 · Last updated May 14, 2026
Summary
This study tested the drug pembrolizumab in 21 people with recurrent respiratory papillomatosis (RRP), a condition where HPV causes non-cancerous growths in the throat, windpipe, or lungs. The goal was to see if the drug could shrink these growths and reduce the need for frequent surgeries. Researchers measured response using scope scores and tumor scans, and also tracked side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT RESPIRATORY PAPILLOMATOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
NorthShore University HealthSystem
Evanston, Illinois, 60208, United States
Conditions
Explore the condition pages connected to this study.